600079 ST人福
交易中 12-23 10:13:23
资讯
新帖
简况
ST人福(600079.SH)：招商生科累计增持2%股份
中金财经 · 12-22 18:47
ST人福(600079.SH)：招商生科累计增持2%股份
中粮资本：ST人福风险不传导至公司资产
证券之星 · 12-19
中粮资本：ST人福风险不传导至公司资产
ST人福(600079.SH)：HW252001片获得药物临床试验批准通知书
智通财经 · 12-19
ST人福(600079.SH)：HW252001片获得药物临床试验批准通知书
ST人福涨5.03%，太平洋一个月前给出“买入”评级
证券之星 · 12-19
ST人福涨5.03%，太平洋一个月前给出“买入”评级
从麻醉一哥到ST人福：一场资本游戏后的生死蜕变
新浪证券 · 12-17
从麻醉一哥到ST人福：一场资本游戏后的生死蜕变
因巨额资金违规占用等多项违规被罚，人福医药将“戴帽”
新京报 · 12-15
因巨额资金违规占用等多项违规被罚，人福医药将“戴帽”
人福医药宣布将于12月15日暂停交易以实施其他风险警示，交易将于12月16日恢复
美股速递 · 12-12
人福医药宣布将于12月15日暂停交易以实施其他风险警示，交易将于12月16日恢复
人福医药(600079.SH)：咪达唑仑注射液获德国上市许可批准
智通财经 · 12-11
人福医药(600079.SH)：咪达唑仑注射液获德国上市许可批准
人福医药（600079）披露子公司撤回药品注册申请，12月03日股价下跌3.33%
证券之星 · 12-03
人福医药（600079）披露子公司撤回药品注册申请，12月03日股价下跌3.33%
人福医药最新公告：子公司撤回重组质粒-肝细胞生长因子注射液药品注册申请
证券之星 · 12-02
人福医药最新公告：子公司撤回重组质粒-肝细胞生长因子注射液药品注册申请
人福医药最新公告：子公司HWS117注射液获得临床试验批准通知书
证券之星 · 11-28
人福医药最新公告：子公司HWS117注射液获得临床试验批准通知书
人福医药(600079.SH)：二甲磺酸利右苯丙胺胶囊上市许可申请获受理
智通财经 · 11-21
人福医药(600079.SH)：二甲磺酸利右苯丙胺胶囊上市许可申请获受理
每周股票复盘：人福医药（600079）实控人变更为招商局集团
证券之星 · 11-16
每周股票复盘：人福医药（600079）实控人变更为招商局集团
人福医药（600079）披露控股股东及实际控制人变更公告，11月14日股价下跌0.19%
证券之星 · 11-14
人福医药（600079）披露控股股东及实际控制人变更公告，11月14日股价下跌0.19%
人福医药：公司始终专注于医药主业的发展
证券日报 · 11-14
人福医药：公司始终专注于医药主业的发展
人福医药(600079.SH)：HW231019片进入II期临床试验研究
智通财经 · 11-12
人福医药(600079.SH)：HW231019片进入II期临床试验研究
每周股票复盘：人福医药（600079）两款新药获临床试验批准
证券之星 · 11-09
每周股票复盘：人福医药（600079）两款新药获临床试验批准
人福医药（600079）股东招商生命科技(武汉)有限公司质押9793.36万股，占总股本6%
证券之星 · 11-07
人福医药（600079）股东招商生命科技(武汉)有限公司质押9793.36万股，占总股本6%
人福医药（600079）披露HWH217片获得药物临床试验批准通知书，11月06日股价上涨0.25%
证券之星 · 11-06
人福医药（600079）披露HWH217片获得药物临床试验批准通知书，11月06日股价上涨0.25%
人福医药(600079.SH)：HWH217片用于治疗(WHO第1组)动脉性肺动脉高压临床试验获批准
智通财经 · 11-06
人福医药(600079.SH)：HWH217片用于治疗(WHO第1组)动脉性肺动脉高压临床试验获批准
公司概况
公司名称：
人福医药集团股份公司
所属行业：
医药制造业
上市日期：
1997-06-06
主营业务：
人福医药集团股份公司的主营业务是药品的研发、生产和销售。公司的主要产品是枸橼酸舒芬太尼注射液、注射用盐酸瑞芬太尼、盐酸氢吗啡酮注射液、盐酸纳布啡注射液、盐酸阿芬太尼注射液、注射用苯磺酸瑞马唑仑、米非司酮制剂、祖卡木颗粒、复方木尼孜其颗粒、注射用尿激酶、硫酸新霉素原料药、黄体酮原料药。
发行价格：
5.22
{"stockData":{"symbol":"600079","market":"SH","secType":"STK","nameCN":"ST人福","latestPrice":19.25,"timestamp":1766456003000,"preClose":19.35,"halted":0,"volume":16892271,"delay":0,"changeRate":-0.0052,"floatShares":1543000000,"shares":1632000000,"eps":0.8753,"marketStatus":"交易中","change":-0.1,"latestTime":"12-23 10:13:23","open":19.26,"high":19.35,"low":18.93,"amount":323000000,"amplitude":0.0217,"askPrice":19.26,"askSize":113,"bidPrice":19.25,"bidSize":23,"shortable":0,"etf":0,"ttmEps":0.8753,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1766460600000},"marketStatusCode":2,"adr":0,"adjPreClose":19.35,"symbolType":"stock","openAndCloseTimeList":[[1766453400000,1766460600000],[1766466000000,1766473200000]],"highLimit":20.32,"lowLimit":18.38,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":1632225965,"isCdr":false,"pbRate":1.67,"roa":"--","peRate":21.99246,"roe":"9.2%","epsLYR":0.82,"committee":-0.144227,"marketValue":31420000000,"turnoverRate":0.0109,"status":1,"floatMarketCap":29706000000},"requestUrl":"/m/hq/s/600079/wiki","defaultTab":"wiki","newsList":[{"id":"2593489454","title":"ST人福(600079.SH)：招商生科累计增持2%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2593489454","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593489454?lang=zh_cn&edition=full","pubTime":"2025-12-22 18:47","pubTimestamp":1766400422,"startTime":"0","endTime":"0","summary":"格隆汇12月22日丨ST人福(600079.SH)公布，公司于2025年12月22日收到招商生科《关于增持人福医药集团股份公司股份实施结果的告知函》，2025年7月17日至2025年12月22日，招商生科通过上海证券交易所交易系统以集中竞价交易方式累计增持公司股份32,644,497股，占公司总股本的2%，增持金额合计为65,417.15万元(不含交易费用)，本次增持计划实施完毕。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251222/31881799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0070","600079","BK0188","BK0239","BK0012","BK0096","BK0028","BK0185"],"gpt_icon":0},{"id":"2592516420","title":"中粮资本：ST人福风险不传导至公司资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2592516420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592516420?lang=zh_cn&edition=full","pubTime":"2025-12-19 20:52","pubTimestamp":1766148725,"startTime":"0","endTime":"0","summary":"ST人福股票由中粮信托设立的破产重整服务信托持有，中粮信托依据信托合同约定提供受托服务，ST人福股票为该破产重整服务信托的信托财产，独立于中粮信托固有财产，也独立于中粮信托管理的其他产品的信托财产，ST人福自身的风险不会直接传导至中粮资本或中粮信托的其他资产与业务。公司将持续密切关注ST人福的整改进展、经营状况、财务状况。关于ST人福的未来发展，请以对方公告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900036458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600079","BK0096","BK0185","BK0188","BK0272","002423","BK0028","BK0239","BK0012","BK0010","BK0070"],"gpt_icon":0},{"id":"2592975159","title":"ST人福(600079.SH)：HW252001片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2592975159","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592975159?lang=zh_cn&edition=full","pubTime":"2025-12-19 15:46","pubTimestamp":1766130403,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST人福(600079.SH)发布公告，公司全资子公司湖北生物医药产业技术研究院有限公司近日收到国家药品监督管理局核准签发的HW252001片的《药物临床试验批准通知书》，同意开展用于特发性肺纤维化适应症的临床试验。HW252001片拟用于特发性肺纤维化的治疗，是一款口服的小分子新药。截至目前，该项目累计研发投入约为2,000万元人民币。特发性肺纤维化(IPF)是一种致病原因不明的间质性肺疾病，具有组织病理学/影像学特征，表现为肺功能进行性下降，出现急性加重和呼吸衰竭，预后较差。IPF的主要治疗方式为抗纤维化药物治疗，用于延缓肺功能下降和疾病进展，目前尚无根治性治疗手段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0096","BK0188","BK0028","600079","BK0070","BK0185","BK0239","BK0012"],"gpt_icon":0},{"id":"2592156720","title":"ST人福涨5.03%，太平洋一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2592156720","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592156720?lang=zh_cn&edition=full","pubTime":"2025-12-19 15:31","pubTimestamp":1766129488,"startTime":"0","endTime":"0","summary":"今日ST人福（600079）涨5.03%，收盘报19.22元。2025年11月5日，太平洋研究员谭紫媚,张懿发布了对人福医药的研报《人福医药：招商局赋能利好发展，多产品获批贡献增量》，该研报对人福医药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为33.02%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为开源证券的蔡明子。ST人福（600079）个股概况：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900017611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600079","601099"],"gpt_icon":0},{"id":"2592961096","title":"从麻醉一哥到ST人福：一场资本游戏后的生死蜕变","url":"https://stock-news.laohu8.com/highlight/detail?id=2592961096","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592961096?lang=zh_cn&edition=full","pubTime":"2025-12-17 15:07","pubTimestamp":1765955220,"startTime":"0","endTime":"0","summary":" 曾被誉为“麻醉一哥”的人福医药，在2025年岁末迎来一记重击。因年报财务数据虚假记载，公司收到湖北证监局的《行政处罚事先告知书》，股票自12月15日起停牌，复牌后简称变更为“ST人福（维权）”。其背后，是一场由大股东当代集团主导的资本游戏逐渐失控的故事。 ST帽子既是一次警醒，也可能成为重生的起点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-12-17/doc-inhcavhm7558747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600079","BK0185","BK0188","BK0028","BK0070","BK0239","BK0012","BK0096"],"gpt_icon":0},{"id":"2591464330","title":"因巨额资金违规占用等多项违规被罚，人福医药将“戴帽”","url":"https://stock-news.laohu8.com/highlight/detail?id=2591464330","media":"新京报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591464330?lang=zh_cn&edition=full","pubTime":"2025-12-15 19:24","pubTimestamp":1765797840,"startTime":"0","endTime":"0","summary":"《行政处罚事先告知书》显示，人福医药自2020年至2022年期间存在多项违法事实。除资金占用问题外，人福医药定期报告还存在虚假记载。基于以上违法事实，湖北证监局决定，对人福医药原控股股东当代集团处以900万元的罚款，对人福医药给予警告，并处以850万元的罚款。2025年，招商局集团通过司法重整正式入主人福医药。在企业治理方面，招商局入主后，人福医药内控与合规体系迅速向央企标准靠拢。","market":"us","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2025/12/wangl88202512151850162832788.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2025/12/wangl88202512151850162832788.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1765797848168289.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1765797848168289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK0012","BK0185","BK0028","BK0070","600079","BK0188","BK0096","BK0239"],"gpt_icon":0},{"id":"1144440220","title":"人福医药宣布将于12月15日暂停交易以实施其他风险警示，交易将于12月16日恢复","url":"https://stock-news.laohu8.com/highlight/detail?id=1144440220","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144440220?lang=zh_cn&edition=full","pubTime":"2025-12-12 18:34","pubTimestamp":1765535666,"startTime":"0","endTime":"0","summary":"人福医药宣布将于12月15日暂停其股票交易，以实施其他风险警示，预计交易将于12月16日恢复。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0185","BK0096","BK0012","BK0188","BK0028","600079","BK0070","BK0239"],"gpt_icon":0},{"id":"2590593405","title":"人福医药(600079.SH)：咪达唑仑注射液获德国上市许可批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590593405","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590593405?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:15","pubTimestamp":1765440941,"startTime":"0","endTime":"0","summary":"智通财经APP讯，人福医药(600079.SH)公告，公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”)收到德国联邦药品和医疗器械管理局(BfArM)核准签发的咪达唑仑注射液的上市许可批准信。公告显示咪达唑仑注射液获得德国联邦药品和医疗器械管理局(BfArM)的上市许可，被批准的适应症包括：1)在诊断或治疗性操作前后及过程中进行清醒镇静(无论是否联合局部麻醉);2)成人麻醉诱导前的术前用药、麻醉诱导、以及与其他麻醉剂作为镇静药物联合使用;儿童麻醉诱导前的术前用药;3)重症监护病房(ICU)中的镇静。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0239","BK0185","600079","FDXMmain","BK0028","FDAXmain","BK0070","FDXSmain","BK0188","BK0096"],"gpt_icon":0},{"id":"2588011992","title":"人福医药（600079）披露子公司撤回药品注册申请，12月03日股价下跌3.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588011992","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588011992?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:04","pubTimestamp":1764752656,"startTime":"0","endTime":"0","summary":"截至2025年12月3日收盘，人福医药报收于18.57元，较前一交易日下跌3.33%，最新总市值为303.1亿元。公司于近日发布公告称，其控股子公司武汉光谷人福生物医药有限公司收到国家药品监督管理局签发的《药品注册申请终止通知书》，同意撤回重组质粒-肝细胞生长因子注射液的注册申请。截至目前，该项目累计研发投入约1.6亿元，收购日可辨认资产分摊金额为2.38亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300025645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0028","BK0188","BK0185","BK0239","BK0012","BK0096","600079"],"gpt_icon":0},{"id":"2588097034","title":"人福医药最新公告：子公司撤回重组质粒-肝细胞生长因子注射液药品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2588097034","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588097034?lang=zh_cn&edition=full","pubTime":"2025-12-02 18:49","pubTimestamp":1764672572,"startTime":"0","endTime":"0","summary":"人福医药公告称，公司控股子公司光谷人福收到国家药品监督管理局签发的《药品注册申请终止通知书》，同意其撤回重组质粒-肝细胞生长因子注射液的注册申请。光谷人福于2024年12月递交上市注册申请，截至目前累计研发投入约为1.6亿元。公司决定主动撤回本次申请，将根据监管要求和技术要求完善研究资料后重新申报。预计该事项不会对公司当期业绩造成重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200029746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0239","BK0185","600079","BK0028","BK0070","BK0188","BK0096"],"gpt_icon":0},{"id":"2586178565","title":"人福医药最新公告：子公司HWS117注射液获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586178565","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586178565?lang=zh_cn&edition=full","pubTime":"2025-11-28 18:20","pubTimestamp":1764325223,"startTime":"0","endTime":"0","summary":"人福医药(600079.SH)公告称，全资子公司湖北生物医药产业技术研究院有限公司近日收到国家药品监督管理局核准签发的HWS117注射液的《药物临床试验批准通知书》。HWS117注射液为一款新型长效FSH药物，拟通过延长FSH在体内的半衰期，满足减少注射频率、提高治疗依从性的临床需求。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800027686.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","600079","BK0028","BK0239","BK0070","BK0188","BK0185","BK0096"],"gpt_icon":0},{"id":"2585419708","title":"人福医药(600079.SH)：二甲磺酸利右苯丙胺胶囊上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2585419708","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585419708?lang=zh_cn&edition=full","pubTime":"2025-11-21 15:38","pubTimestamp":1763710735,"startTime":"0","endTime":"0","summary":"智通财经APP讯，人福医药 发布公告，公司控股子公司宜昌人福药业有限责任公司近日收到国家药品监督管理局核准签发的二甲磺酸利右苯丙胺胶囊的药品注册上市许可申请《受理通知书》。据悉，二甲磺酸利右苯丙胺胶囊原研最早于美国获批上市，用于治疗成人和6岁及以上儿科患者的注意缺陷多动障碍，以及成人中度至重度暴食症。根据国家药品监督管理局官网显示，国内目前暂无二甲磺酸利右苯丙胺胶囊上市，也无相关产品获批进口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0239","BK0012","BK0185","600079","BK0028","BK0096","BK0070"],"gpt_icon":0},{"id":"2583510756","title":"每周股票复盘：人福医药（600079）实控人变更为招商局集团","url":"https://stock-news.laohu8.com/highlight/detail?id=2583510756","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583510756?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:12","pubTimestamp":1763237536,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，人福医药报收于20.78元，较上周的20.46元上涨1.56%。本周关注点公司公告汇总：人福医药实控人变更为招商局集团，招商生科合计控制公司26.62%表决权。截至目前，项目累计研发投入约2000万元人民币。招商证券关于人福医药详式权益变动报告书之2025年第三季度持续督导意见2025年7月30日，人福医药完成董事会换届，招商生科提名5名非独立董事，合计控制公司26.62%表决权，成为公司控股股东，实际控制人变更为招商局集团。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001150.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0185","BK0028","BK0070","600079","BK0188","BK0096","BK0239"],"gpt_icon":0},{"id":"2583850274","title":"人福医药（600079）披露控股股东及实际控制人变更公告，11月14日股价下跌0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583850274","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583850274?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:47","pubTimestamp":1763131646,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，人福医药报收于20.78元，较前一交易日下跌0.19%，最新总市值为339.18亿元。该股当日开盘20.72元，最高20.94元，最低20.66元，成交额达3.33亿元，换手率为1.04%。公司近日发布公告，招商证券出具了关于人福医药详式权益变动报告书之2025年第三季度持续督导意见。公告显示，2025年7月30日，人福医药完成董事会换届，招商生科提名5名非独立董事，合计控制公司26.62%表决权，成为公司控股股东，实际控制人变更为招商局集团。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0070","BK0028","BK0012","600079","BK0239","BK0096","BK0188"],"gpt_icon":0},{"id":"2583022115","title":"人福医药：公司始终专注于医药主业的发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2583022115","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583022115?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:10","pubTimestamp":1763129400,"startTime":"0","endTime":"0","summary":"证券日报网讯人福医药（维权）11月14日在互动平台回答投资者提问时表示，公司始终专注于医药主业的发展，持续推进“归核聚焦”工作，优化资产结构，强化细分领域竞争优势。2025年前三季度，公司实现归母净利润16.89亿元，同比增长6.22%，2025年三季度末公司资产负债率降至40.53%，资产结构持续改善。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-14/doc-infxktkn8977482.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-14/doc-infxktkn8977482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0096","BK0028","BK0012","159938","BK0185","BK1515","BK0188","BK1574","09939","BK0070","600079","BK0239","BK1161"],"gpt_icon":0},{"id":"2582032868","title":"人福医药(600079.SH)：HW231019片进入II期临床试验研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2582032868","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582032868?lang=zh_cn&edition=full","pubTime":"2025-11-12 15:46","pubTimestamp":1762933596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，人福医药(600079.SH)发布公告，公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”，公司持有其80%的股权)近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了HW231019片II期临床试验登记信息。试验目的：1)探索HW231019片用于腹部手术后镇痛的疗效和安全性;2)初步探索HW231019片用于术后镇痛的用法用量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"人福医药(600079.SH)：HW231019片进入II期临床试验研究","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0096","BK0239","BK0028","BK0070","600079","BK0185","BK0188"],"gpt_icon":0},{"id":"2582866965","title":"每周股票复盘：人福医药（600079）两款新药获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2582866965","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582866965?lang=zh_cn&edition=full","pubTime":"2025-11-09 01:43","pubTimestamp":1762623789,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，人福医药报收于20.46元，较上周的21.14元下跌3.22%。公司公告汇总人福医药关于普瑞巴林缓释片获得药物临床试验批准通知书的公告证券代码：600079 证券简称：人福医药 编号：临 2025-118人福医药集团股份公司控股子公司宜昌人福药业有限责任公司近日收到国家药品监督管理局核准签发的普瑞巴林缓释片《药物临床试验批准通知书》。截至目前，宜昌人福对该研发项目累计投入约5,500万元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","BK0239","BK0096","BK0185","BK0028","600079","BK0012"],"gpt_icon":0},{"id":"2581800650","title":"人福医药（600079）股东招商生命科技(武汉)有限公司质押9793.36万股，占总股本6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581800650","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581800650?lang=zh_cn&edition=full","pubTime":"2025-11-07 18:25","pubTimestamp":1762511130,"startTime":"0","endTime":"0","summary":"证券之星消息，人福医药11月7日公开信息显示，股东招商生命科技(武汉)有限公司向招商银行股份有限公司武汉分行合计质押9793.36万股，占总股本6.0%。质押详情见下表：截止本公告日，股东招商生命科技(武汉)有限公司已累计质押股份9793.36万股，占其持股总数的74.86%，股东李杰已累计质押股份5200.0万股，占其持股总数的59.94%。人福医药主营业务：药品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700031796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0239","BK0188","BK0028","BK0070","BK0185","BK0096","600079"],"gpt_icon":0},{"id":"2581918560","title":"人福医药（600079）披露HWH217片获得药物临床试验批准通知书，11月06日股价上涨0.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581918560","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581918560?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:06","pubTimestamp":1762437988,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘，人福医药报收于20.35元，较前一交易日上涨0.25%，最新总市值为332.16亿元。该股当日开盘20.3元，最高20.46元，最低20.18元，成交额达4.23亿元，换手率为1.35%。公司近日发布公告称，其全资子公司湖北生物医药产业技术研究院有限公司收到国家药品监督管理局签发的HWH217片《药物临床试验批准通知书》，同意该药品开展用于治疗动脉性肺动脉高压的临床试验。HWH217片为化学药品2.3类新复方制剂，目前国内市场尚无同类复方制剂获批用于该适应症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600037971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0012","600079","BK0185","BK0188","BK0028","BK0239","BK0096"],"gpt_icon":0},{"id":"2581594220","title":"人福医药(600079.SH)：HWH217片用于治疗(WHO第1组)动脉性肺动脉高压临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2581594220","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581594220?lang=zh_cn&edition=full","pubTime":"2025-11-06 16:08","pubTimestamp":1762416481,"startTime":"0","endTime":"0","summary":"智通财经APP讯，人福医药(600079.SH)公告，公司全资子公司湖北生物医药产业技术研究院有限公司近日收到国家药品监督管理局核准签发的HWH217片的《药物临床试验批准通知书》，同意本品开展“用于治疗(WHO第1组)动脉性肺动脉高压”的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0185","BK0096","BK0188","BK0070","600079","BK0239","BK0012","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766456010088,"stockEarnings":[{"period":"1week","weight":0.0661},{"period":"1month","weight":0.0099},{"period":"3month","weight":-0.0838},{"period":"6month","weight":-0.064},{"period":"1year","weight":-0.1824},{"period":"ytd","weight":-0.1596}],"compareEarnings":[{"period":"1week","weight":0.0128},{"period":"1month","weight":0.0215},{"period":"3month","weight":0.025},{"period":"6month","weight":0.1335},{"period":"1year","weight":0.1631},{"period":"ytd","weight":0.1687}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"人福医药集团股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"69442人(较上一季度增加38.71%)","perCapita":"22222股","listingDate":"1997-06-06","address":"湖北省武汉市洪山区东湖高新区高新大道666号","registeredCapital":"163222万元","survey":" 人福医药集团股份公司的主营业务是药品的研发、生产和销售。公司的主要产品是枸橼酸舒芬太尼注射液、注射用盐酸瑞芬太尼、盐酸氢吗啡酮注射液、盐酸纳布啡注射液、盐酸阿芬太尼注射液、注射用苯磺酸瑞马唑仑、米非司酮制剂、祖卡木颗粒、复方木尼孜其颗粒、注射用尿激酶、硫酸新霉素原料药、黄体酮原料药。","listedPrice":5.22},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ST人福(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ST人福(600079)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ST人福,600079,ST人福股票,ST人福股票老虎,ST人福股票老虎国际,ST人福行情,ST人福股票行情,ST人福股价,ST人福股市,ST人福股票价格,ST人福股票交易,ST人福股票购买,ST人福股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ST人福(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ST人福(600079)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}